The first trial is SOLAR-STAGE: a Phase 3, multicenter, open-label study to evaluate the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in staging of men with newly diagnosed unfavorable ...

The proposed acquisition of Eczacıbaşı-Monrol will: Build on existing partnership in Lu-177 creating a leading manufacturer ...

But the conversation also covered the impact of AI on work which was considered from various perspectives. Carolyn Hicks said ...

This is the second part of a three-part series written by Carolyn Krause. Many of the elements were synthesized using an Oak ...

PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy. PYLCLARI® (INN ...

The proposed acquisition of Eczacıbaşı-Monrol will: Build on existing partnership in Lu-177 creating a leading manufacturer of the isotope Add 12 PET sites to Curium’s existing network in ...

ST. LOUIS, April 23, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its SOLAR clinical trials ...

Curium, a world leader in nuclear medicine, announced that today in the Netherlands the first commercial dose of PYLCLARI® has been sold. PYLCLARI® (INN: Piflufolastat ...

About Curium Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe.